期刊文献+

SAMe-TT 2R 2评分在非瓣膜性房颤患者抗凝疗效中的评估 被引量:1

Evaluation of SAMe-TT 2R 2 score in the anticoagulation effect of patients with non-valvular atrial fibrillation
在线阅读 下载PDF
导出
摘要 目的评价SAMe-TT 2R 2评分对非瓣膜性房颤使用华法林的患者中的抗凝疗效的评估作用,探讨SAMe-TT 2R 2评分与缺血性卒中事件、出血事件的相关性。方法以石河子大学医学院第一附属医院2018年1月—2019年1月住院治疗,确诊为非瓣膜性房颤并口服华法林抗凝的患者作为观察对象,进行为期10月的随访。通过患者的国际标准化比值(INR),计算患者的抗凝治疗范围内时间百分比(Time in Therapeutic Range,TTR),并对所有患者进行SAMe-TT 2R 2评分。运用χ2检验、Spearman秩相关、ROC曲线分析评估SAMe-TT 2R 2评分对患者抗凝疗效的预测能力。随访期内收集缺血性卒中和出血事件的发生情况,分析上述事件与SAMe-TT 2R 2评分的相关性。结果190例患者平均TTR为(46.76±21.99)%,SAMe-TT 2R 2分数与患者的TTR呈负相关(P=0.001),ROC曲线下面积为0.661,P=0.001,约登指数0.203对应的临界值取整数为4分,敏感度和特异度分别为72.6%和47.7%,提示SAMe-TT 2R 2对预测TTR<65%有一定的价值。随访期间共有5例患者发生缺血性卒中事件,25例患者发生不同程度出血事件,11例患者发生全因死亡事件,上述事件在各个SAMe-TT 2R 2分值的发生分布差异无统计学意义(P>0.05)。结论在非瓣膜性房颤并使用华法林抗凝治疗的患者中,SAMe-TT 2R 2评分对使用华法林抗凝治疗患者的抗凝有效性具有一定的预测能力,可将SAMe-TT 2R 2评分作为预测华法林抗凝疗效的预测的指标。 Objective To evaluate the anticoagulant effect of SAMe-TT 2R 2 in patients with non-valvular atrial fibrillation treated with warfarin,and to explore the correlation between SAMe-TT 2R 2 and ischemic stroke events and bleeding events.Methods Patients who were diagnosed as non-valvular atrial fibrillation and with oral warfarin were enrolled in the First Affiliated Hospital of Shihezi University School of Medical College in January 2018-January 2019,and for 10 months of follow-up.Collecting patients'International normalization ratio(INR),calculating the Time in therapeutic range(TTR),and the SAMe-TT2 R2 score.Andχ2 test,Spearman rank correlation and ROC curve analysis were used to evaluate the predictive ability of SAMe-TT2 R2 score on anticoagulant efficacy in patients.Follow-up was conducted to investigate the incidence of ischemic stroke or hemorrhagic events and explore the relationship with the SAMe-TT2 R2 score.Results The mean TTR of 190 patients was 46.76%±21.99%,and the score of SAMe-TT 2 R2 was negatively correlated with the TTR of the patients(P=0.001),the area under the ROC curve was 0.661,P=0.001,The critical value corresponding was 4 points,and the sensitivity and specificity were 72.6%and 47.7%,respectively suggesting that SAMe-TT 2R 2 had certain value in predicting TTR<65%.During follow-up,a total of 5 patients had ischemic stroke,25 patients had different degrees of bleeding,and 11 patients had all-cause death,different SAMe-TT 2R 2 scores showed no statistical significance(P>0.05).Conclusion In patients with non-valvular atrial fibrillation treated with warfarin anticoagulant,the SAMe-TT 2R 2 score has a certain predictive ability for the anticoagulant efficacy of patients treated with warfarin anticoagulant,and the SAMe-TT 2R 2 score could be used as an indicator for predicting the anticoagulant efficacy of warfarin.
作者 杨诗琪 王丽 李岳明 王楠 YANG Shiqi;WANG Li;LI Yueming;WANG Nan(Department of Cardiology,The First Affiliated Hospital,School of Medicine,Shihezi University,Shihezi 832000,China)
出处 《广州医药》 2020年第2期31-35,共5页 Guangzhou Medical Journal
基金 院级重点领域创新团队项目(TJ2016-001)。
关键词 非瓣膜性房颤 华法林 SAMe-TT2 R2评分 抗凝疗效评估 Non-valvular atrial fibrillation Warfarin SAMe-TT 2R 2 score Evaluation of anticoagulant efficacy
  • 相关文献

参考文献2

二级参考文献17

  • 1胡大一,张鹤萍,孙艺红,姜立清.华法林与阿司匹林预防非瓣膜性心房颤动患者血栓栓塞的随机对照研究[J].中华心血管病杂志,2006,34(4):295-298. 被引量:163
  • 2Hirsh J, Fuster V, Ansell J, et al. American Heart Association/ American College of Cardiology Foundation guide to warfarin therapy. J Am Coil Cardiol, 2003,41:1633-1652.
  • 3Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 2007, 146:S57-867.
  • 4Hu D, Sun Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. J Am Coil Cardiol, 2008, 52: 865-868.
  • 5Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med, 2005,352:2285-2293.
  • 6Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 1999, 353:717-719.
  • 7Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl) :eddS- 88S.
  • 8Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl) :e152S-184S.
  • 9Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenetics of coumarinic oral anticoagulants. Pharmacogenomics, 2010, 11 : 493 -496.
  • 10Schulman S, Parpia S, Stewart C, et al. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med, 2011,155:653-659.

共引文献620

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部